Objective It has been reported that D-galactose (D-gal) can model subacute aging, and aluminum (AI) acts as a neurotoxin, but combined effects of them have not been reported. The present work aimed to reveal the e...
详细信息
Objective It has been reported that D-galactose (D-gal) can model subacute aging, and aluminum (AI) acts as a neurotoxin, but combined effects of them have not been reported. The present work aimed to reveal the effect of combined administration of D-gal and A1 in mice and compare the effect of D-gal treatment with that of A1 treatment. Meth- ods A1 was intragastricaHy administered and D-gal was subcutaneously injected into Kunming mice for 10 consecutive weeks. Learning and memory, eholinergic systems, as well as protein levels of amyloid β (Aβ) and hyperphosphorylated tau were determined using Morri water maze test, biochemical assays and immunohistochemical staining, respectively. Results The mice with combined treatment had obvious learning and memory deficits, and showed decreases in brain ace- tylcholine (ACh) level and in activities of choline acetyltransferase (CHAT) and acetyleholinesterase (ACHE). Formation of senile plaque (SP)-like and neurofibrillary tangle (NFT)-like structures was also observed. The behavioral and pathologi- cal changes persisted for at least 6 weeks after withdrawal of D-gal and A1. Conclusion Combined use of D-gal and A1 is an effective way to establish the non-transgenic Alzheimer's disease (AD) animal model, and is useful for studies of AD pathogenesis and therapeutic evaluation.
β-Amyloid (Aβ) over-expression and tau hyperphosphorylation are considered to be the central events in the pathogenesis of Alzheimer's disease (AD).Studies on them may help elucidate the precise molecular patho...
详细信息
β-Amyloid (Aβ) over-expression and tau hyperphosphorylation are considered to be the central events in the pathogenesis of Alzheimer's disease (AD).Studies on them may help elucidate the precise molecular pathogenesis of *** now,although tau protein and Aβ remain the foci of AD research,the etiopathogenesis of AD and effective drugs for AD treatment are still largely *** present review was mainly focused on the molecular mechanism of Aβ aggregation-related impairment and the pathways leading to tau hyperphosphorylation,based on which some promising therapeutic targets for AD were also proposed.
目的研究Nogo-66受体(NgR)能否作为药物治疗阿尔茨海默病(Alzheimer s disease,AD)的潜在靶标。此靶标是否同时具有促进皮质神经元突起再生和抑制β淀粉样蛋白(amyloidβ-protein,Aβ)生成的双重作用。方法 (1)体外无血清培养新生大鼠...
详细信息
目的研究Nogo-66受体(NgR)能否作为药物治疗阿尔茨海默病(Alzheimer s disease,AD)的潜在靶标。此靶标是否同时具有促进皮质神经元突起再生和抑制β淀粉样蛋白(amyloidβ-protein,Aβ)生成的双重作用。方法 (1)体外无血清培养新生大鼠皮质神经元,采用神经元特异性烯醇化酶(NSE)和微管相关蛋白2(MAP2)免疫细胞化学染色法进行神经元鉴定;(2)应用MTT法检测不同浓度的Nogo-66活性片段Nogo-P4(3.5μM、7μM、14μM)对皮质神经元的作用,通过细胞形态学观察,突起生长状况的定量分析,观察Nogo-P4对皮质神经元突起生长的影响,采用ELISA法测定培养液中Aβ42的含量,分析Nogo-P4对皮质神经元所产生Aβ42的影响;(3)在体外培养的大鼠皮质神经元中,分别加入NgR阻断剂NEP1-40、NgR下游信号分子ROCK的抑制剂Y-27632和PKC抑制剂G 6976,采用上述指标,研究NgR影响皮质神经元突起生长和Aβ42生成的分子机制。
暂无评论